
The US Food and Drug Administration has published its own complete response letter (CRL) for Summit Therapeutics’ ivonescimab, putting the agency’s written reasons for the rejection on the record on 18 November 2026, three days after Summit announced the rejection. The letter, dated 13 November, says 93% of progression-free survival events in the pivotal trial occurred in patients enrolled in China and asks for a new multiregional trial.
What happened
The FDA issued the letter on 13 November 2026, one day before the 14 November goal date for BLA 761524, the biologics license application for ivonescimab (AK112/SMT112). Summit made the decision public on 15 November. On 18 November, STAT reported that the FDA had itself disclosed its reasons for rejecting the drug, and the full letter is now available through the FDA’s openFDA transparency data.
The application sought approval of ivonescimab with platinum chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy, based on the HARMONi trial. The FDA’s letter states that it “cannot approve this application in its present form” and that substantial evidence of effectiveness is not established and the benefit-risk profile does not support approval.
Key details in the letter
The letter lists four clinical and statistical deficiencies.
- Applicability to the US population. The FDA says the applicability of the prespecified primary endpoint, progression-free survival (PFS), to the US population “cannot be established as 93% of events (257 of 275 PFS events) occurred in patients enrolled in China.”
- Modest effect. The PFS result was statistically significant but showed a modest improvement in median PFS for an add-on to chemotherapy, with no statistically significant improvement in final overall survival (OS) and no substantial difference in overall response rate.
- Exploratory follow-up. The submitted post-hoc PFS and OS analyses based on longer follow-up are “exploratory only”. The OS analyses are further limited by different data cutoff dates across regions, which the FDA attributes to follow-up ending earlier for patients enrolled in China, where clinical sites closed during 2025.
- Risk. The modest PFS gain does not outweigh the risks of adding ivonescimab to chemotherapy, including serious immune-related toxicities and toxicities related to VEGF inhibition.
| Item | What the letter says |
|---|---|
| Letter date | 13 November 2026 |
| Application | BLA 761524, received 14 November 2025 |
| PFS events in China | 257 of 275 (93%) |
| China share of study population | 60% |
| Resubmission window | One year under 21 CFR 601.3(b), extension can be requested |
Background and context
The FDA letter records that the trial was originally designed as a single-country study enrolling exclusively in China and was later modified to add North America and the European Union. Chinese enrolment ran from January to November 2022, and enrolment in North America and the EU did not start until May 2023. The agency says it had raised concerns about this enrolment approach at a Type A meeting in March 2023 and again at the pre-BLA meeting in May 2025.
Trade press had flagged the survival question before the letter. pharmaphorum reported that the pivotal HARMONi trial did not show a statistically significant OS improvement, although it significantly extended the time to progression or death, and that Summit had filed anyway, citing signs that OS in the international cohort was moving toward significance. Fierce Pharma’s headline on the published letter framed it as citing China-heavy data beyond the survival miss.
The disclosure itself follows the FDA’s complete response letter initiative. The letter ends with a notice that, consistent with the agency’s public statements, it is working to redact and publish the CRL, removing trade secret information, confidential commercial information and personal identifiers under 21 CFR Part 20. For how these letters work, see the CASRAI explainers on the FDA complete response letter and the openFDA CRL database.
Reaction
Summit’s chief executive, Dr Maky Zanganeh, said in the company’s statement, as quoted by pharmaphorum, that the industry’s responsibility is to continue advancing science. pharmaphorum also reported that attention has now turned to the HARMONi-3 trial comparing ivonescimab plus chemotherapy with Keytruda plus chemotherapy in first-line NSCLC, which could report OS and PFS results for squamous disease by the end of the year, with non-squamous data due in the first half of 2027. Trading data compiled by the tracker pdufa.bio shows Summit shares fell 16.5% on the first trading day after the announcement; that move may include news other than the decision.
What it means for researchers, universities and research offices
The letter is a rare, specific statement of how the FDA reads a trial that began in one country and widened later. Several points are concrete:
- Enrolment design. The agency ties its concern to regional distribution of events, not only to the total sample size. Sponsors and academic investigators planning trials with large non-US enrolment can read the letter as a worked example of the question reviewers will ask. The FDA names ICH E17 and its guidance on oncology multiregional development programs as the reference points; see the CASRAI guide to ICH E17.
- Endpoints. A statistically significant PFS result did not carry the application where OS was not significant and response rate showed no substantial difference. Protocol and statistical analysis plan teams should note the stated weight on OS; see the guide to designing a clinical trial.
- Follow-up consistency. Different data cutoff dates by region weakened the OS analyses. Site closures and follow-up termination are operational decisions that research offices and sponsors control, and the letter shows they can limit later evidence.
- Early meetings. The agency’s stated concerns date from March 2023 and May 2025, so documentation of FDA advice and how it was addressed matters for any institution sponsoring an investigator-initiated study intended to support a license.
What happens next
The FDA recommends that Summit submit results from a new adequate and well-controlled multiregional trial showing a statistically significant and clinically meaningful improvement in OS, PFS or another endpoint measuring clinical benefit, sufficient to outweigh the toxicity profile, and meet the agency before starting it to discuss design and endpoints. Under 21 CFR 601.3, Summit must resubmit or take another available action within one year of the letter date, or the FDA may treat the lack of response as a request to withdraw the application. The letter also asks for a safety update and English translations of approved foreign labeling with any resubmission.
Sources
- US Food and Drug Administration, Complete Response Letter, BLA 761524, 13 November 2026, via the openFDA CRL record (PDF: CRL_BLA761524_20261113)
- STAT, FDA discloses reasons for rejecting Summit drug, 18 November 2026
- pharmaphorum, FDA won’t approve Summit, Akeso’s ivonescimab, November 2026
- Fierce Pharma, FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss, November 2026
- pdufa.bio, Ivonescimab CRL, 13 November 2026
- Summit Therapeutics, Form 8-K, 15 November 2026







